Esoglaz-L Capsule SR is a combination pharmaceutical formulation containing Levosulpiride 75 mg and Esomeprazole 40 mg, designed for the management of gastrointestinal disorders. Levosulpiride, a selective dopamine D2 receptor antagonist, exhibits prokinetic and antiemetic properties by enhancing gastric motility and accelerating gastric emptying, thereby alleviating symptoms such as nausea, vomiting, bloating, and dyspepsia. Esomeprazole, a proton pump inhibitor, suppresses gastric acid secretion by irreversibly inhibiting the H+/K+ ATPase enzyme system in gastric parietal cells, providing effective acid control and promoting mucosal healing in acid-related conditions. The sustained-release formulation ensures prolonged therapeutic plasma concentrations, optimizing symptom relief and improving patient compliance. Esoglaz-L Capsule SR is indicated for the treatment of gastroesophageal reflux disease (GERD), functional dyspepsia, gastritis, and other acid-peptic disorders where impaired motility and acid hypersecretion coexist. It should be administered under medical supervision, with dosage adjustments based on clinical response and tolerability. Caution is advised in patients with hepatic or renal impairment. Common adverse effects may include headache, dizziness, and gastrointestinal disturbances. Contraindications include hypersensitivity to either component or related compounds. This combination therapy offers a synergistic approach, addressing both motility dysfunction and acid suppression for comprehensive gastrointestinal symptom management.

Dosage & How to Use